Atorvastatin and fenofibric acid differentially affect the release of adipokines in the visceral and subcutaneous cultures of adipocytes that were obtained from patients with and without mixed dyslipidemia

Pharmacological Reports

Volumn 63, Issue 5, 2011, Pages 1124-1136

  Łabuzek, Krzysztof ^a   Bułdak, Łukasz ^a   Duława Bułdak, Anna ^a   Bielecka, Anna ^a   Krysiak, Robert ^a   Madej, Andrzej ^a   Okopień, Bogusław ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Adipocytes; Adipokines; Hypolipidemic agents; Pleiotropic effects; Preadipocytes

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ATORVASTATIN; FENOFIBRIC ACID; INTERLEUKIN 6; LEPTIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; RESISTIN;

ADIPOCYTE; ADULT; AGED; ARTICLE; CELL FUNCTION; CELL SECRETION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFECT; DRUG MECHANISM; DYSLIPIDEMIA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HORMONE ACTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; IN VITRO STUDY; INTRAABDOMINAL FAT; LIPID COMPOSITION; MALE; METABOLIC SYNDROME X; MONOTHERAPY; PLEIOTROPY; SUBCUTANEOUS FAT;

EID: 83155172717     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(11)70631-4     Document Type: Article

References (40)

1. Anderlová K, Dolezalová R, Housová J, Bosanska L, Haluzikova D, Kremen J, Skrha J, Haluzík M: Influence of PPAR-α agonist fenofibrate on insulin sensitivity and selected adipose tissue-derived hormones in obese women with type 2 diabetes. Physiol Res, 2007, 56, 579-586.
2. Blanco-Colio LM, Martín-Ventura JL, Gómez-Guerrero C, Masramon X, de Teresa E, Farsang C, Gaw A, et al.: Adiponectin plasma levels are increased by atorvastatin treatment in subjects at high cardiovascular risk. Eur J Pharmacol, 2008, 586, 259-265.
3. Bulcǎ;o C, Giuffrida FM, Ribeiro-Filho FF, Ferreira SR: Are the beneficial cardiovascular effects of simvastatin and metformin also associated with a hormonedependent mechanism improving insulin sensitivity? Braz J Med Biol Res, 2007, 40, 229-235. (Pubitemid 46237855)
4. Chen Y, Ohmori K, Mizukawa M, Yoshida J, Zeng Y, Zhang L, Shinomiya K et al.: Differential impact of atorvastatin vs pravastatin on progressive insulin resistance and left ventricular diastolic dysfunction in a rat model of type II diabetes. Circ J, 2007, 71, 144-152. (Pubitemid 46045564)
5. Choi KC, Ryu OH, Lee KW, Kim HY, Seo JA, Kim SG, Kim NH et al.: Effect of PPAR-alpha and -gamma agonist on the expression of visfatin, adiponectin, and TNFalpha in visceral fat of OLETF rats. Biochem Biophys Res Commun, 2005, 336, 747-753. (Pubitemid 41338332)
6. Chu CH, Lee JK, Lam HC, Lu CC, Sun CC, Wang MC, Chuang MJ, Wei MC: Atorvastatin does not affect insulin sensitivity and the adiponectin or leptin levels in hyperlipidemic type 2 diabetes. J Endocrinol Invest, 2008, 31, 42-47. (Pubitemid 351403827)
7. Chu CS, Lee KT, Lee MY, Su HM, Voon WC, Sheu SH, Lai WT: Effects of atorvastatin and atorvastatin withdrawal on soluble CD40L and adipocytokines in patients with hypercholesterolaemia. Acta Cardiol, 2006, 61, 263-269.
8. Crandall DL, Quinet EM, El Ayachi S, Hreha AL, Leik CE, Savio DA, Juhan-Vaque I, Alessi MC: Modulation of adipose tissue development by pharmacological inhibition of PAI-1. Arterioscler Thromb Vasc Biol, 2006, 26, 2209-2215. (Pubitemid 44465713)
9. Damci T, Tatliagac S, Osar Z, Ilkova H: Fenofibrate treatment is associated with better glycemic control and lower serum leptin and insulin levels in type 2 diabetic patients with hypertriglyceridemia. Eur J Inten Med, 2003, 14, 357-360. (Pubitemid 40090259)
10. Desager JP, Horsmans Y: Clinical pharmacokinetics of 3-hydroxy-3- methylglutaryl-coenzyme A reductase inhibitors. Clin Pharmacokinet, 1996, 31, 348-371.
11. Devaraj S, Siegel D, Jialal I: Simvastatin (40 mg/day), adiponectin levels, and insulin sensitivity in subjects with the metabolic syndrome. Am J Cardiol, 2007, 100, 1397-1399. (Pubitemid 47576016)
12. Dimitrow PP, Jawień M. Anti-inflammatory effect of atorvastatin in patients with aortic sclerosis or mild aortic stenosis independent of hypercholesterolemia. Pharmacol Rep, 2010, 62, 1250-1254.
13. Forst T, Pfützner A, Lübben G, Weber M, Marx N, Karagiannis E, Koehler C et al.: Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk-the PIOSTAT Study. Metabolism, 2007, 56, 491-496. (Pubitemid 46437254)
14. Frick M, Dulak J, Cisowski J, Józkowicz A, Zwick R, Alber H, Dichtl Wet al.: Statins differentially regulate vascular endothelial growth factor synthesis in endothelial and vascular smooth muscle cells. Atherosclerosis, 2003, 170, 229-236. (Pubitemid 37377794)
15. Gouni-Berthold I, Berthold HK, Chamberland JP, Krone W, Mantzoros CS: Short-term treatment with ezetimibe, simvastatin or their combination does not alter circulating adiponectin, resistin or leptin levels in healthy men. Clin Endocrinol, 2008, 68, 536-541. (Pubitemid 351388705)
16. Haluzik MM, Lacinova Z, Dolinkova M, Haluzikova D, Housa D, Horinek A, Vernerova Z et al.: Improvement of insulin sensitivity after peroxisome proliferator-activated receptor-alpha agonist treatment is accompanied by paradoxical increase of circulating resistin levels. Endocrinology, 2006, 147, 4517-4524. (Pubitemid 44268403)
17. He G, Pedersen SB, Bruun JM, Lihn AS, Richelsen B: Metformin, but not thiazolidinediones, inhibits plasminogen activator inhibitor-1 production in human adipose tissue in vitro. Horm Metab Res, 2003, 35, 18-23. (Pubitemid 36403287)
18. Hiuge A, Tenenbaum A, Maeda N, Benderly M, Kumada M, Fisman EZ, Tanne D et al.: Effects of peroxisome proliferator-activated receptor ligands, bezafibrate and fenofibrate, on adiponectin level. Arterioscler Thromb Vasc Biol, 2007, 27, 635-641.
19. Jeong S, Han M, Lee H, Kim M, Kim J, Nicol CJ, Kim BH et al.: Effects of fenofibrate on high-fat diet-induced body weight gain and adiposity in female C57BL/6J mice. Metabolism, 2004, 53, 1284-1289. (Pubitemid 39222088)
20. Keating GM, Omrod D: Micronised fenofibrate. An updated review of its clinical efficacy in the management of dyslipidaemia. Drugs, 2002, 62, 1909-1944.
21. Khan T, Hamilton MP, Mundy DI, Chua SC, Scherer PE: Impact of simvastatin on adipose tissue: pleiotropic effects in vivo. Endocrinology, 2009, 150, 5262-5272.
22. Koh KK, Quon MJ, Han SH, Chung WJ, Ahn JY, Seo YH, Choi YS, Shin EK: Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia. J Am Coll Cardiol, 2005, 45, 1649-1653. (Pubitemid 40704501)
23. Koh KK, Quon MJ, Han SH, Lee Y, Ahn JY, Kim SJ, Koh Y et al.: Simvastatin improves flow-mediated dilation but reduces adiponectin levels and insulin sensitivity in hypercholesterolemic patients. Diabetes Care, 2008, 31, 776-782.
24. Koizumi N, Fullwood NJ, Bairaktaris G, Inatomi T, Kinoshita S, Quantock AJ: Cultivation of corneal epithelial cells on intact and denuded human amniotic membrane. Invest Ophthalmol Vis Sci, 2000, 41, 2506-2513. (Pubitemid 30624377)
25. Krysiak R, Łabuzek K, Okopień B: Effect of atorvastatin and fenofibric acid on adipokine release from visceral and subcutaneous adipose tissue of patients with mixed dyslipidemia and normolipidemic subjects. Pharmacol Rep, 2009, 61, 1134-1145.
26. Laumen H, Skurk T, Hauner H: The HMG-CoA reductase inhibitor rosuvastatin inhibits plasminogen activator inhibitor-1 expression and secretion in human adipocytes. Atherosclerosis, 2008, 196, 565-573.
27. Lumeng CN, Bodzin JL, Saltiel AR: Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest, 2007, 117, 175-184. (Pubitemid 46048464)
28. Miller DB, Spence JD: Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet, 1998, 34, 155-162. (Pubitemid 28077673)
29. Murata M, Kaji H, Takahashi Y, Iida K, Mizuno I, Okimura Y, Abe H, Chihara K: Stimulation by eicosapentaenoic acids of leptin mRNA expression and its secretion in mouse 3T3-L1 adipocytes in vitro. Biochem Biophys Res Commun, 2000, 270, 343-348. (Pubitemid 30446839)
30. Nakano S, Inada Y, Masuzaki H, Tanaka T, Yasue S, Ishii T, Arai N et al.: Bezafibrate regulates the expression and enzyme activity of 11β-hydroxysteroid dehydrogenase type 1 in murine adipose tissue and 3T3-L1 adipocytes. Am J Physiol Endocrinol Metab, 2007, 292, E1213-E1222. (Pubitemid 46536523)
31. Nagila A, Permpongpaiboon T, Tantrarongroj S, Porapakkham P, Chinwattana K, Deakin S, Porntadavity S: Effect of atorvastatin on paraoxonase1 (PON1) and oxidative status. Pharmacol Rep, 2009, 61, 892-898.
32. Ogawa S, Takeuchi K, Sugimura K, Fukuda M, Lee R, Ito S, Sato T: Bezafibrate reduces blood glucose in type 2 diabetes mellitus. Metabolism, 2000, 49, 331-334. (Pubitemid 30146563)
33. Oki K, Koide J, Nakanishi S, Nakashima R, Yamane K: Fenofibrate increases high molecular weight adiponectin in subjects with hypertriglyceridemia. Endocr J, 2007, 54, 431-435. (Pubitemid 47105431)
34. Otto C, Otto B, Frost RJ, Vogeser M, Pfeiffer AF, Spranger J, Parhofer KG: Short-term therapy with atorvastatin or fenofibrate does not affect plasma ghrelin, resistin or adiponectin levels in type 2 diabetic patients with mixed hyperlipoproteinaemia. Acta Diabetol, 2007, 44, 65-68. (Pubitemid 46835447)
35. Panigrahy D, Kaipainen A, Huang S, Butterfield CE, Barnés CM, Fannon M, Laforme AM et al.: PPARαagonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition. Proc Nat Acad Sci USA, 2008, 105, 985-990. (Pubitemid 351282068)
36. Saito S, Fujiwara T, Matsunaga T, Minaqawa K, Fukui K, Fukuda I, Osanai T, Okumura K: Increased adiponectin synthesis in the visceral adipose tissue in men with coronary artery disease treated with pravastatin: A role of the attenuation of oxidative stress. Atherosclerosis, 2008, 199, 78-83.
37. Thomas J, Bramlett KS, Montrose C, Foxworthy P, Eacho PI, McCann D, Cao G et al.: A chemical switch regulates fibrate specificity for peroxisome proliferatoractivated receptor α (PPARα) versus liver X receptor. J Biol Chem, 2003, 278, 2403-2410. (Pubitemid 36801314)
38. Yin WH, Jen HL, Chen JW, Lin SJ, Young MS: Differential effects of peroxisome proliferator-activated receptor ligands and sulfonylurea plus statin treatment on plasma concentrations of adipokines in type 2 diabetes with dyslipidemia. Diabetes Metab, 2006, 32, 229-235. (Pubitemid 43966746)
39. Yin X, Tu L, Yang H: Effect of simvastatin on IL-6 and adiponectin secretion and mRNA expression in 3T3-L1 adipocytes. J Huazhong Univ Sci Technolog Med Sci, 2007, 27, 248-251.
40. Yu YH, Zhu H: Chronological changes in metabolism and functions of cultured adipocytes: a hypotesis for cell aging in mature adipocytes. Am J Physiol Endocrinol Metab, 2004, 286, E402-E410.